Tempus AI is quietly turning genetic tests and clinical records into a healthcare data platform that drugmakers and hospitals can plug into, making the system more useful every time it’s used. With growth holding up, costs improving, and big-name funds taking notice, the bigger question is whether its debt and high expectations around AI could still trip it up.Read more
Tempus AI aims to turn cancer testing into a powerful data business, with more hospitals using its genomic tests and drug makers paying for access to its growing library of real‑world patient insights. The big question is whether new insurance coverage for newer blood-based tests and AI-driven “dry lab” tools arrives fast enough to justify today’s high expectations.Read more
Tempus AI aims to use genetic testing and artificial intelligence to help doctors and drugmakers make better cancer decisions, and it’s growing fast through more tests and deeper partnerships with big drug companies. The big question is whether it can turn that momentum into steady profits before tougher competition, payment delays, and shifting rules slow it down.Read more
Catalysts About Tempus AI Tempus AI provides AI driven molecular diagnostics and data products to support clinical decision making and drug development. What are the underlying business or industry changes driving this perspective?Read more
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
